Table 4.
Clinical characteristics and course of SARS-CoV-2 breakthrough infections in 20 patients on chronic hemodialysis.
| No. | Age | BMI | Diabetes | pKTx | Vintage | Vaccination | isMeds | IgG | nTiter | CT | Remission/Days | Course |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | 50–55 | 22 | No | Yes | 7.2 | 3 times mRNA | ldST | >433 | 100 | 21 | 18 | Mild |
| 2. | 55–60 | 31 | No | Yes | 10.5 | 3 times mRNA | no | >433 | 100 | 17 | 14 | Mild |
| 3. | 55–60 | 29 | No | No | 2.1 | 3 times mRNA | no | 0 | <30 | 17 | 16 | Mild |
| 4. | 30–35 | 19 | No | Yes | 5.8 | 2 times mRNA | no | >433 | 98 | 22 | 7 | Mild |
| 5. | 60–65 | 35 | Yes | No | 0.4 | 2 times mRNA | no | 70 | 48 | 9 | 29 | Mild |
| 6. | 70–75 | 28 | Yes | No | 1.6 | wild, 2 times mRNA | no | >433 | 84 | 15 | 12 | Mild |
| 7. | 50–55 | 32 | Yes | No | 4.0 | 3 times mRNA | no | >433 | 99 | 13 | 8 | Mild |
| 8. | 35–40 | 31 | Yes | Yes | 2.1 | 3 times mRNA | no | >433 | 100 | 18 | 13 | Mild |
| 9. | 80–85 | 19 | No | No | 3.4 | 3 times mRNA | no | >433 | 100 | 18 | 13 | Mild |
| 10. | 30–35 | 20 | Yes | No | 0.7 | 3 times mRNA | no | >433 | 97 | 14 | 15 | Mild |
| 11. | 80–85 | 24 | No | No | 0.9 | 4 times mRNA | no | >433 | 99 | 16 | 14 | Mild |
| 12. | 70–75 | 24 | No | No | 4.4 | 3 times mRNA | no | >433 | 100 | 16 | 12 | Mild |
| 13. | 75–80 | 20 | No | No | 7.9 | 3 times mRNA | no | >433 | 99 | 13 | 11 | Mild |
| 14. | 60–65 | 30 | Yes | No | 0.8 | 3 times mRNA | ldST | 372 | 51 | 19 | 8 | Mild |
| 15. | 60–65 | 25 | No | No | 3.8 | 3 times mRNA | No | >433 | 98 | 21 | 7 | Mild |
| 16. | 50–55 | 27 | No | Yes | 1.6 | 4 times mRNA | No | >433 | 97 | 18 | 10 | Mild |
| 17. | 70–75 | 23 | No | No | 14.7 | 3 times mRNA | No | >433 | 99 | 16 | 12 | Mild |
| 18. | 60–65 | 32 | No | No | 1.1 | 3 times mRNA | ldST | >433 | 98 | 19 | 12 | Mild |
| 19. | 75–80 | 25 | No | No | 8.7 | 3 times mRNA | No | >433 | 100 | 12 | 8 | Mild |
| 20. | 80–85 | 19 | Yes | No | 0.6 | 1 time mRNA | ST | 0 | 0 | 14 | 12 | Mild |
Age in years, BMI = body mass index in kg/m2, pKTx = prior kidney transplant, vintage = time on dialysis in years, isMeds = presence of immunosuppressive medication, wild = infection before vaccination, ldST = low-dose steroids ≤5 mg, IgG = SARS-CoV-2 IgG antibody titers in BAU/mL, nTiter = neutralizing titer (capacity) of IgG antibodies in %, CT = crossing threshold-level on PCR-testing at time of diagnosis, remission = time from first diagnosis to complete PCR proven resolution in days (weekly measurements), one patient was accidentally diagnosed on hospital admission, all others on routine pre-dialysis testing. Mean time to complete remission of PCR testing was 14 days. No patient developed signs of lower respiratory tract infection by SARS-CoV-2 or was hospitalized due to SARS-CoV-2 infection of the upper airways. One patient died of other causes while tested positive with SARS-CoV-2. This patient showed normal results on chest X-ray and pulmonary CT. One patient with myeloma received SARS-CoV-2 specific i.v. antibodies, 75% of pts were male.